Dose Ranging and Dose Frequency of LIPO-102

Overview

Dose Ranging and Dose Frequency of LIPO-102

Full Title of Study: “A Dose-Ranging and Dose Frequency Study Evaluating the Safety and Efficacy of LIPO-102 for the Reduction of Abdominal Subcutaneous Adipose Tissue”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Single (Participant)
  • Study Primary Completion Date: February 2010

Interventions

  • Drug: LIPO-102
    • Subcutaneous Injection
  • Drug: Placebo
    • Placebo

Arms, Groups and Cohorts

  • Experimental: LIPO-102
    • LIPO-102
  • Experimental: Placebo
    • Placebo

Clinical Trial Outcome Measures

Primary Measures

  • Safety: physical examinations, laboratory tests, AE assessment
    • Time Frame: 4 weeks treatment and 4 weeks follow up

Secondary Measures

  • Efficacy: change in subcutaneous abdominal adipose tissue thickness
    • Time Frame: 4 weeks treatment and 4 weeks follow up

Participating in This Clinical Trial

Inclusion Criteria

  • Male or non pregnant female – Good general health – Sufficient abdominal fat for injections – Signed informed consent Exclusion Criteria:

  • Known hypersensitivity to study drugs – Treatment with an investigational agent within 30 days of first dose

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 65 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Neothetics, Inc
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.